Courtagen raises $8M for biomarker work

Massachusetts-based Courtagen has raised $8 million from 67 investors to support development of protein biomarkers for disease detection using technology it bought from Decision Biomarkers in 2009, according to Xconomy. The company was previously known as Avantra Bioscience. Article

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.